Chun-Yang Fan
Concepts (278)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Head and Neck Neoplasms | 14 | 2010 | 268 | 1.820 |
Why?
| Carcinoma, Squamous Cell | 15 | 2010 | 318 | 1.700 |
Why?
| DNA Methylation | 13 | 2009 | 548 | 1.150 |
Why?
| DNA Glycosylases | 5 | 2011 | 19 | 1.080 |
Why?
| Gene Silencing | 7 | 2009 | 119 | 1.070 |
Why?
| Promoter Regions, Genetic | 11 | 2009 | 475 | 1.060 |
Why?
| Mitochondria | 3 | 2011 | 402 | 0.530 |
Why?
| DNA Repair | 5 | 2008 | 193 | 0.520 |
Why?
| Adaptor Proteins, Signal Transducing | 5 | 2009 | 197 | 0.490 |
Why?
| Polymerase Chain Reaction | 11 | 2009 | 453 | 0.490 |
Why?
| Kidney Neoplasms | 2 | 2008 | 177 | 0.480 |
Why?
| Carcinoma, Non-Small-Cell Lung | 2 | 2007 | 154 | 0.470 |
Why?
| DNA, Neoplasm | 10 | 2008 | 147 | 0.470 |
Why?
| Nuclear Proteins | 5 | 2009 | 242 | 0.470 |
Why?
| Neoplasm Proteins | 4 | 2005 | 322 | 0.420 |
Why?
| Laryngeal Neoplasms | 3 | 2007 | 42 | 0.400 |
Why?
| Vascular Endothelial Growth Factor A | 2 | 2009 | 201 | 0.380 |
Why?
| CpG Islands | 3 | 2008 | 108 | 0.380 |
Why?
| Lung Neoplasms | 2 | 2007 | 606 | 0.360 |
Why?
| Microsatellite Instability | 1 | 2009 | 17 | 0.350 |
Why?
| Fatty Liver | 1 | 2011 | 127 | 0.350 |
Why?
| Immunohistochemistry | 7 | 2012 | 973 | 0.340 |
Why?
| Mitochondrial Proteins | 2 | 2007 | 90 | 0.330 |
Why?
| Receptors, Vascular Endothelial Growth Factor | 1 | 2008 | 22 | 0.320 |
Why?
| Port-Wine Stain | 1 | 2008 | 14 | 0.320 |
Why?
| Oxygen | 1 | 2011 | 326 | 0.310 |
Why?
| O(6)-Methylguanine-DNA Methyltransferase | 2 | 2005 | 9 | 0.310 |
Why?
| Genes, p16 | 3 | 2005 | 9 | 0.300 |
Why?
| Lymph Nodes | 2 | 2007 | 260 | 0.300 |
Why?
| DNA, Mitochondrial | 4 | 2011 | 112 | 0.290 |
Why?
| N-Glycosyl Hydrolases | 1 | 2007 | 6 | 0.290 |
Why?
| DNA-(Apurinic or Apyrimidinic Site) Lyase | 1 | 2007 | 16 | 0.290 |
Why?
| Carcinoma, Renal Cell | 1 | 2008 | 105 | 0.290 |
Why?
| Skin | 3 | 2010 | 409 | 0.290 |
Why?
| Aged | 15 | 2011 | 9310 | 0.290 |
Why?
| Adenoma | 1 | 2008 | 110 | 0.280 |
Why?
| Mitochondria, Liver | 1 | 2007 | 70 | 0.280 |
Why?
| Cisplatin | 3 | 2007 | 278 | 0.280 |
Why?
| Proteoglycans | 2 | 2003 | 80 | 0.270 |
Why?
| Fibroma | 1 | 2006 | 39 | 0.270 |
Why?
| Aged, 80 and over | 8 | 2009 | 3129 | 0.250 |
Why?
| Liver | 1 | 2011 | 1115 | 0.250 |
Why?
| Middle Aged | 16 | 2011 | 12069 | 0.250 |
Why?
| Membrane Glycoproteins | 2 | 2003 | 240 | 0.250 |
Why?
| Survival Analysis | 5 | 2009 | 653 | 0.250 |
Why?
| Carcinoma, Hepatocellular | 1 | 2007 | 191 | 0.240 |
Why?
| Prognosis | 7 | 2007 | 1942 | 0.240 |
Why?
| Humans | 36 | 2013 | 49974 | 0.240 |
Why?
| DNA Repair Enzymes | 1 | 2004 | 44 | 0.240 |
Why?
| Ataxia Telangiectasia | 1 | 2004 | 6 | 0.230 |
Why?
| Salivary Ducts | 1 | 2003 | 3 | 0.230 |
Why?
| Salivary Gland Neoplasms | 1 | 2003 | 7 | 0.230 |
Why?
| Adenocarcinoma, Clear Cell | 1 | 2003 | 34 | 0.230 |
Why?
| Receptors, Cytoplasmic and Nuclear | 1 | 2003 | 64 | 0.230 |
Why?
| Liver Neoplasms | 1 | 2007 | 326 | 0.220 |
Why?
| Obesity | 1 | 2011 | 1113 | 0.210 |
Why?
| Adult | 14 | 2011 | 13236 | 0.210 |
Why?
| Nitric Oxide Synthase Type III | 2 | 2013 | 78 | 0.200 |
Why?
| Female | 22 | 2012 | 26472 | 0.200 |
Why?
| Male | 21 | 2012 | 25241 | 0.200 |
Why?
| Epigenesis, Genetic | 1 | 2004 | 374 | 0.180 |
Why?
| Transcription Factors | 1 | 2003 | 561 | 0.180 |
Why?
| Antineoplastic Agents | 2 | 2010 | 1171 | 0.170 |
Why?
| Skin Transplantation | 2 | 2010 | 43 | 0.170 |
Why?
| Carrier Proteins | 4 | 2005 | 304 | 0.160 |
Why?
| Skin Neoplasms | 4 | 2008 | 488 | 0.160 |
Why?
| Tumor Suppressor Proteins | 2 | 2011 | 128 | 0.150 |
Why?
| Loss of Heterozygosity | 2 | 2008 | 77 | 0.150 |
Why?
| DNA Damage | 2 | 2011 | 301 | 0.150 |
Why?
| Survival Rate | 3 | 2009 | 894 | 0.140 |
Why?
| Neoplasm Invasiveness | 4 | 2007 | 267 | 0.130 |
Why?
| Graft Survival | 3 | 2011 | 150 | 0.120 |
Why?
| Ki-67 Antigen | 2 | 2011 | 57 | 0.120 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2011 | 595 | 0.120 |
Why?
| Calcium-Calmodulin-Dependent Protein Kinases | 2 | 2005 | 33 | 0.120 |
Why?
| Algorithms | 2 | 2008 | 615 | 0.120 |
Why?
| Immunoenzyme Techniques | 4 | 2013 | 143 | 0.120 |
Why?
| Cadherins | 2 | 2005 | 68 | 0.120 |
Why?
| Prostatic Neoplasms | 2 | 2008 | 394 | 0.120 |
Why?
| Thyroid Neoplasms | 2 | 2007 | 110 | 0.120 |
Why?
| Keratosis | 2 | 2003 | 13 | 0.110 |
Why?
| Receptors, Cell Surface | 1 | 2013 | 122 | 0.100 |
Why?
| Base Sequence | 2 | 2004 | 643 | 0.100 |
Why?
| Carcinoma in Situ | 2 | 2003 | 73 | 0.100 |
Why?
| Lymphangioma, Cystic | 1 | 2011 | 10 | 0.100 |
Why?
| Arteriovenous Malformations | 1 | 2013 | 67 | 0.100 |
Why?
| Laryngectomy | 3 | 2007 | 28 | 0.100 |
Why?
| Leukoplakia, Oral | 1 | 2011 | 6 | 0.100 |
Why?
| Aminolevulinic Acid | 1 | 2011 | 8 | 0.100 |
Why?
| Endothelium, Lymphatic | 1 | 2011 | 12 | 0.100 |
Why?
| Lasers, Dye | 1 | 2011 | 9 | 0.100 |
Why?
| Wound Healing | 2 | 2010 | 204 | 0.100 |
Why?
| Antigens, CD | 1 | 2013 | 219 | 0.100 |
Why?
| Photosensitizing Agents | 1 | 2011 | 21 | 0.100 |
Why?
| Cell Line, Tumor | 4 | 2010 | 1403 | 0.100 |
Why?
| Lymphatic Abnormalities | 1 | 2011 | 22 | 0.100 |
Why?
| Propranolol | 1 | 2012 | 78 | 0.100 |
Why?
| Microtubule-Associated Proteins | 1 | 2011 | 67 | 0.100 |
Why?
| Photochemotherapy | 1 | 2011 | 34 | 0.100 |
Why?
| Biopsy | 3 | 2011 | 584 | 0.100 |
Why?
| Homeodomain Proteins | 1 | 2011 | 80 | 0.100 |
Why?
| Taxoids | 1 | 2010 | 37 | 0.090 |
Why?
| Laser Therapy | 1 | 2011 | 84 | 0.090 |
Why?
| Drug Resistance, Multiple | 1 | 2010 | 23 | 0.090 |
Why?
| Hemangioma | 1 | 2012 | 83 | 0.090 |
Why?
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2010 | 56 | 0.090 |
Why?
| Follow-Up Studies | 4 | 2011 | 2182 | 0.090 |
Why?
| Gene Deletion | 1 | 2011 | 266 | 0.090 |
Why?
| Neoplasm Staging | 3 | 2007 | 740 | 0.090 |
Why?
| Gene Expression Regulation, Neoplastic | 4 | 2010 | 828 | 0.090 |
Why?
| Mice, Transgenic | 1 | 2011 | 555 | 0.080 |
Why?
| Disease Models, Animal | 2 | 2011 | 1455 | 0.080 |
Why?
| Animals | 8 | 2011 | 13187 | 0.080 |
Why?
| Drug Resistance, Neoplasm | 1 | 2010 | 308 | 0.080 |
Why?
| Sulfites | 1 | 2008 | 1 | 0.080 |
Why?
| Paraffin Embedding | 1 | 2008 | 53 | 0.080 |
Why?
| Microsatellite Repeats | 1 | 2008 | 37 | 0.080 |
Why?
| Blood Glucose | 1 | 2011 | 439 | 0.080 |
Why?
| Neoplasm Seeding | 1 | 2008 | 4 | 0.080 |
Why?
| Mice | 4 | 2011 | 5739 | 0.080 |
Why?
| Chordoma | 1 | 2008 | 8 | 0.080 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2004 | 989 | 0.080 |
Why?
| Recurrent Laryngeal Nerve | 1 | 2007 | 13 | 0.080 |
Why?
| Skull Base Neoplasms | 1 | 2008 | 21 | 0.080 |
Why?
| Laryngeal Nerves | 1 | 2007 | 16 | 0.080 |
Why?
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2005 | 55 | 0.080 |
Why?
| Receptors, Thyrotropin | 1 | 2007 | 7 | 0.080 |
Why?
| Apoptosis Regulatory Proteins | 2 | 2005 | 86 | 0.080 |
Why?
| Symporters | 1 | 2007 | 17 | 0.080 |
Why?
| Methylation | 2 | 2007 | 122 | 0.080 |
Why?
| Pattern Recognition, Automated | 1 | 2007 | 42 | 0.070 |
Why?
| Image Enhancement | 1 | 2007 | 54 | 0.070 |
Why?
| Risk Factors | 3 | 2008 | 3613 | 0.070 |
Why?
| Cell Proliferation | 1 | 2011 | 1007 | 0.070 |
Why?
| Precancerous Conditions | 1 | 2008 | 83 | 0.070 |
Why?
| Prostate | 1 | 2008 | 117 | 0.070 |
Why?
| Carcinoma, Papillary | 1 | 2007 | 48 | 0.070 |
Why?
| Transgenes | 1 | 2007 | 55 | 0.070 |
Why?
| Neoplasm Recurrence, Local | 2 | 2008 | 614 | 0.070 |
Why?
| Child, Preschool | 3 | 2012 | 3871 | 0.070 |
Why?
| Image Interpretation, Computer-Assisted | 1 | 2007 | 106 | 0.070 |
Why?
| Child | 5 | 2012 | 6847 | 0.070 |
Why?
| Cell Nucleus | 1 | 2007 | 183 | 0.070 |
Why?
| MicroRNAs | 1 | 2010 | 353 | 0.070 |
Why?
| Syndecans | 2 | 2003 | 34 | 0.070 |
Why?
| Artificial Intelligence | 1 | 2007 | 80 | 0.070 |
Why?
| Protein Transport | 1 | 2007 | 180 | 0.070 |
Why?
| RNA, Messenger | 2 | 2007 | 1105 | 0.070 |
Why?
| Syndecan-1 | 2 | 2003 | 72 | 0.070 |
Why?
| Genomics | 1 | 2008 | 286 | 0.070 |
Why?
| Adenomatous Polyposis Coli Protein | 1 | 2005 | 2 | 0.070 |
Why?
| Receptors, Atrial Natriuretic Factor | 1 | 2005 | 8 | 0.060 |
Why?
| Atrial Natriuretic Factor | 1 | 2005 | 21 | 0.060 |
Why?
| Ear, Inner | 1 | 2005 | 17 | 0.060 |
Why?
| Melanoma | 1 | 2008 | 285 | 0.060 |
Why?
| Guanine | 1 | 2004 | 40 | 0.060 |
Why?
| Cell Physiological Phenomena | 1 | 2004 | 3 | 0.060 |
Why?
| Cell Cycle Proteins | 1 | 2005 | 166 | 0.060 |
Why?
| Cytochromes c | 1 | 2003 | 29 | 0.060 |
Why?
| DNA Adducts | 1 | 2004 | 78 | 0.060 |
Why?
| Salivary Proteins and Peptides | 1 | 2003 | 8 | 0.060 |
Why?
| Statistics as Topic | 1 | 2003 | 88 | 0.060 |
Why?
| Isoenzymes | 1 | 2003 | 168 | 0.060 |
Why?
| Base Pair Mismatch | 1 | 2003 | 22 | 0.060 |
Why?
| Adenocarcinoma, Follicular | 1 | 2003 | 3 | 0.060 |
Why?
| Adenocarcinoma, Papillary | 1 | 2003 | 5 | 0.060 |
Why?
| Tunica Intima | 1 | 2003 | 54 | 0.050 |
Why?
| Adenoma, Oxyphilic | 1 | 2003 | 11 | 0.050 |
Why?
| Cell Count | 1 | 2003 | 147 | 0.050 |
Why?
| Retrospective Studies | 4 | 2007 | 6108 | 0.050 |
Why?
| DNA-Binding Proteins | 1 | 2005 | 427 | 0.050 |
Why?
| Keratoacanthoma | 1 | 2002 | 7 | 0.050 |
Why?
| Collagen | 1 | 2003 | 206 | 0.050 |
Why?
| Renal Dialysis | 1 | 2003 | 169 | 0.050 |
Why?
| Platelet Aggregation Inhibitors | 1 | 2003 | 172 | 0.050 |
Why?
| Alcohol Drinking | 1 | 2003 | 224 | 0.050 |
Why?
| Combined Modality Therapy | 4 | 2004 | 637 | 0.050 |
Why?
| Lung | 1 | 2005 | 486 | 0.050 |
Why?
| Molecular Sequence Data | 1 | 2003 | 792 | 0.050 |
Why?
| Adolescent | 2 | 2012 | 6356 | 0.050 |
Why?
| Blotting, Western | 2 | 2013 | 601 | 0.050 |
Why?
| Cohort Studies | 1 | 2005 | 1422 | 0.050 |
Why?
| Blood Platelets | 1 | 2003 | 245 | 0.050 |
Why?
| Prevalence | 1 | 2004 | 944 | 0.050 |
Why?
| Tomography, X-Ray Computed | 1 | 2006 | 1159 | 0.050 |
Why?
| Smoking | 1 | 2003 | 511 | 0.040 |
Why?
| Random Allocation | 2 | 2010 | 281 | 0.040 |
Why?
| Quality of Life | 1 | 2004 | 836 | 0.040 |
Why?
| Electrophoresis, Agar Gel | 2 | 2008 | 11 | 0.040 |
Why?
| Sensitivity and Specificity | 2 | 2010 | 861 | 0.040 |
Why?
| Hyperplasia | 2 | 2008 | 96 | 0.030 |
Why?
| Neck Dissection | 2 | 2008 | 31 | 0.030 |
Why?
| Dose-Response Relationship, Drug | 2 | 2011 | 1376 | 0.030 |
Why?
| Fluorouracil | 2 | 2004 | 54 | 0.030 |
Why?
| Photosensitivity Disorders | 2 | 2003 | 10 | 0.030 |
Why?
| Cross-Sectional Studies | 2 | 2012 | 1557 | 0.030 |
Why?
| Infant | 2 | 2012 | 3567 | 0.030 |
Why?
| Lymph Node Excision | 2 | 2004 | 134 | 0.030 |
Why?
| Head | 1 | 2013 | 73 | 0.030 |
Why?
| Actins | 1 | 2013 | 118 | 0.030 |
Why?
| Neck | 1 | 2013 | 99 | 0.030 |
Why?
| Treatment Outcome | 3 | 2011 | 5141 | 0.030 |
Why?
| Lymphocele | 1 | 2011 | 7 | 0.030 |
Why?
| Tissue Survival | 1 | 2011 | 10 | 0.030 |
Why?
| Antigens, Nuclear | 1 | 2011 | 24 | 0.030 |
Why?
| Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 47 | 0.020 |
Why?
| Administration, Topical | 1 | 2011 | 56 | 0.020 |
Why?
| Tissue Culture Techniques | 1 | 2011 | 40 | 0.020 |
Why?
| Transplantation, Heterologous | 1 | 2011 | 74 | 0.020 |
Why?
| Time Factors | 2 | 2010 | 2903 | 0.020 |
Why?
| Mice, Nude | 1 | 2011 | 252 | 0.020 |
Why?
| Neoplasms, Squamous Cell | 1 | 2010 | 7 | 0.020 |
Why?
| Rats | 2 | 2009 | 3305 | 0.020 |
Why?
| Granulation Tissue | 1 | 2010 | 10 | 0.020 |
Why?
| Pharmacogenetics | 1 | 2010 | 52 | 0.020 |
Why?
| Tissue and Organ Harvesting | 1 | 2010 | 23 | 0.020 |
Why?
| Myeloid Cells | 1 | 2010 | 38 | 0.020 |
Why?
| Probability | 1 | 2010 | 164 | 0.020 |
Why?
| Endothelial Cells | 1 | 2011 | 269 | 0.020 |
Why?
| Carcinoma | 1 | 2010 | 138 | 0.020 |
Why?
| Graft Rejection | 1 | 2010 | 161 | 0.020 |
Why?
| Pilot Projects | 1 | 2011 | 699 | 0.020 |
Why?
| Neovascularization, Physiologic | 1 | 2009 | 68 | 0.020 |
Why?
| Thymine | 1 | 2008 | 10 | 0.020 |
Why?
| Chi-Square Distribution | 1 | 2009 | 280 | 0.020 |
Why?
| Centromere | 1 | 2008 | 11 | 0.020 |
Why?
| Microdissection | 1 | 2008 | 19 | 0.020 |
Why?
| Cell Line, Transformed | 1 | 2008 | 72 | 0.020 |
Why?
| Telomere | 1 | 2008 | 36 | 0.020 |
Why?
| Melanocytes | 1 | 2008 | 37 | 0.020 |
Why?
| Gene Dosage | 1 | 2008 | 78 | 0.020 |
Why?
| Fluorescent Dyes | 1 | 2008 | 102 | 0.020 |
Why?
| Iodine | 1 | 2007 | 10 | 0.020 |
Why?
| Genetic Markers | 1 | 2008 | 102 | 0.020 |
Why?
| Predictive Value of Tests | 1 | 2010 | 903 | 0.020 |
Why?
| Mice, Knockout | 1 | 2010 | 841 | 0.020 |
Why?
| Fatal Outcome | 1 | 2008 | 195 | 0.020 |
Why?
| Cluster Analysis | 1 | 2007 | 235 | 0.020 |
Why?
| Epithelial Cells | 1 | 2008 | 209 | 0.020 |
Why?
| Buffers | 1 | 2005 | 9 | 0.020 |
Why?
| Prospective Studies | 1 | 2011 | 2364 | 0.020 |
Why?
| Round Window, Ear | 1 | 2005 | 6 | 0.020 |
Why?
| Injections | 1 | 2005 | 55 | 0.020 |
Why?
| Rats, Inbred Lew | 1 | 2005 | 69 | 0.020 |
Why?
| Phosphates | 1 | 2005 | 47 | 0.020 |
Why?
| Sodium Chloride | 1 | 2005 | 57 | 0.020 |
Why?
| Rats, Sprague-Dawley | 1 | 2009 | 1597 | 0.020 |
Why?
| Protein Isoforms | 1 | 2005 | 119 | 0.020 |
Why?
| Drug Combinations | 1 | 2005 | 123 | 0.020 |
Why?
| Mice, Inbred C57BL | 1 | 2010 | 1816 | 0.020 |
Why?
| Antibodies | 1 | 2005 | 154 | 0.020 |
Why?
| Statistics, Nonparametric | 1 | 2004 | 194 | 0.010 |
Why?
| Reproducibility of Results | 1 | 2007 | 1193 | 0.010 |
Why?
| Disease-Free Survival | 1 | 2005 | 454 | 0.010 |
Why?
| Platelet Adhesiveness | 1 | 2003 | 13 | 0.010 |
Why?
| Elastin | 1 | 2003 | 23 | 0.010 |
Why?
| Polytetrafluoroethylene | 1 | 2003 | 32 | 0.010 |
Why?
| DNA Primers | 1 | 2003 | 207 | 0.010 |
Why?
| Up-Regulation | 1 | 2005 | 452 | 0.010 |
Why?
| Anastomosis, Surgical | 1 | 2003 | 66 | 0.010 |
Why?
| Radiotherapy | 1 | 2004 | 128 | 0.010 |
Why?
| Vascular Patency | 1 | 2003 | 82 | 0.010 |
Why?
| Dogs | 1 | 2003 | 182 | 0.010 |
Why?
| Radiotherapy, Adjuvant | 1 | 2003 | 56 | 0.010 |
Why?
| Myocytes, Smooth Muscle | 1 | 2003 | 86 | 0.010 |
Why?
| Chemotherapy, Adjuvant | 1 | 2003 | 119 | 0.010 |
Why?
| Graft Occlusion, Vascular | 1 | 2003 | 73 | 0.010 |
Why?
| Extracellular Matrix | 1 | 2003 | 111 | 0.010 |
Why?
| Thyroidectomy | 1 | 2003 | 59 | 0.010 |
Why?
| Biopsy, Needle | 1 | 2003 | 183 | 0.010 |
Why?
| Young Adult | 1 | 2012 | 3958 | 0.010 |
Why?
| Lymphatic Metastasis | 1 | 2003 | 224 | 0.010 |
Why?
| Stromal Cells | 1 | 2002 | 72 | 0.010 |
Why?
| Models, Biological | 1 | 2003 | 727 | 0.010 |
Why?
| Risk Assessment | 1 | 2003 | 1259 | 0.010 |
Why?
| Arkansas | 1 | 2004 | 1977 | 0.010 |
Why?
| Diagnosis, Differential | 1 | 2002 | 1037 | 0.010 |
Why?
| Pregnancy | 1 | 2003 | 2607 | 0.010 |
Why?
|
|
Fan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|